PURPOSE: To prospectively evaluate a gadolinium-based collagen-targeting contrast agent, EP-3533, for in vivo magnetic resonance (MR) imaging of myocardial fibrosis in a mouse model of healed myocardial infarction (MI). MATERIALS AND METHODS: All procedures were performed in accordance with protocols approved by the animal care and use committee. MI was induced in eight mice by means of occlusion of the left anterior descending coronary artery followed by reperfusion. Four MR examinations were performed in each animal: one examination before, one examination 1 day after, and two examinations 6 weeks after the MI. For the latter two examinations, electrocardiographically gated inversion-recovery gradient-echo MR images were acquired before and serially (every 5 minutes) after the intravenous injection of either gadopentetate dimeglumine or EP-3533. The image enhancement kinetic properties of the postinfarction scar, normal myocardium, and blood were compared. RESULTS: Dynamic T1-weighted MR imaging revealed the washout time constants for EP-3533 to be significantly longer than those for gadopentetate dimeglumine in regions of postinfarction scarring (mean, 194.8 minutes +/-116.8 [standard deviation] vs 25.5 minutes +/- 4.2; P < .05) and in normal myocardium (mean, 45.4 minutes +/- 16.7 vs 25.1 minutes +/- 9.7; P < .05). Findings on postmortem histologic sections stained for collagen correlated well with EP-3533-enhanced areas seen on inversion-recovery MR images. Fifty minutes after EP-3533 injection, the postinfarction scar tissue samples, as compared with the normal myocardium, had a twofold higher concentration of gadolinium. CONCLUSION: Use of the gadolinium-based collagen-targeting contrast agent, EP-3533, enabled in vivo molecular MR imaging of fibrosis in a mouse model of healed postinfarction myocardial scarring. (c) RSNA, 2008.
PURPOSE: To prospectively evaluate a gadolinium-based collagen-targeting contrast agent, EP-3533, for in vivo magnetic resonance (MR) imaging of myocardial fibrosis in a mouse model of healed myocardial infarction (MI). MATERIALS AND METHODS: All procedures were performed in accordance with protocols approved by the animal care and use committee. MI was induced in eight mice by means of occlusion of the left anterior descending coronary artery followed by reperfusion. Four MR examinations were performed in each animal: one examination before, one examination 1 day after, and two examinations 6 weeks after the MI. For the latter two examinations, electrocardiographically gated inversion-recovery gradient-echo MR images were acquired before and serially (every 5 minutes) after the intravenous injection of either gadopentetate dimeglumine or EP-3533. The image enhancement kinetic properties of the postinfarction scar, normal myocardium, and blood were compared. RESULTS: Dynamic T1-weighted MR imaging revealed the washout time constants for EP-3533 to be significantly longer than those for gadopentetate dimeglumine in regions of postinfarction scarring (mean, 194.8 minutes +/-116.8 [standard deviation] vs 25.5 minutes +/- 4.2; P < .05) and in normal myocardium (mean, 45.4 minutes +/- 16.7 vs 25.1 minutes +/- 9.7; P < .05). Findings on postmortem histologic sections stained for collagen correlated well with EP-3533-enhanced areas seen on inversion-recovery MR images. Fifty minutes after EP-3533 injection, the postinfarction scar tissue samples, as compared with the normal myocardium, had a twofold higher concentration of gadolinium. CONCLUSION: Use of the gadolinium-based collagen-targeting contrast agent, EP-3533, enabled in vivo molecular MR imaging of fibrosis in a mouse model of healed postinfarction myocardial scarring. (c) RSNA, 2008.
Authors: Martin Rohrer; Hans Bauer; Jan Mintorovitch; Martin Requardt; Hanns-Joachim Weinmann Journal: Invest Radiol Date: 2005-11 Impact factor: 6.016
Authors: O P Simonetti; R J Kim; D S Fieno; H B Hillenbrand; E Wu; J M Bundy; J P Finn; R M Judd Journal: Radiology Date: 2001-01 Impact factor: 11.105
Authors: R J Kim; D S Fieno; T B Parrish; K Harris; E L Chen; O Simonetti; J Bundy; J P Finn; F J Klocke; R M Judd Journal: Circulation Date: 1999-11-09 Impact factor: 29.690
Authors: Stuart S Berr; Rene Jack Roy; Brent A French; Zequan Yang; Wesley Gilson; Christopher M Kramer; Frederick H Epstein Journal: Magn Reson Med Date: 2005-05 Impact factor: 4.668
Authors: Zequan Yang; Stuart S Berr; Wesley D Gilson; Marie-Claire Toufektsian; Brent A French Journal: Circulation Date: 2004-02-16 Impact factor: 29.690
Authors: Robert A de Kemp; Frederick H Epstein; Ciprian Catana; Benjamin M W Tsui; Erik L Ritman Journal: J Nucl Med Date: 2010-05-01 Impact factor: 10.057
Authors: Ronald J Beyers; R Scott Smith; Yaqin Xu; Bryan A Piras; Michael Salerno; Stuart S Berr; Craig H Meyer; Christopher M Kramer; Brent A French; Frederick H Epstein Journal: Magn Reson Med Date: 2011-05-31 Impact factor: 4.668
Authors: Stephen H Gilbert; David Benoist; Alan P Benson; Ed White; Steven F Tanner; Arun V Holden; Halina Dobrzynski; Olivier Bernus; Aleksandra Radjenovic Journal: Am J Physiol Heart Circ Physiol Date: 2011-10-21 Impact factor: 4.733
Authors: Heejung Kim; Sung-Jin Lee; Jin Su Kim; Cynthia Davies-Venn; Hong-Jun Cho; Samuel J Won; Eden Dejene; Zhengsheng Yao; Insook Kim; Chang H Paik; David A Bluemke Journal: Nucl Med Commun Date: 2016-12 Impact factor: 1.690